-
International Journal of Chronic Obstructive Pulmonary Disease
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions
(3037) Views (1452) Full article downloads
Authors: Khaled Albouaini, Mohammed Andron, Albert Alahmar, Mohaned Egred
Published Date January 2007
Volume 2007:2(4) Pages 535 - 540
DOI: http://dx.doi.org/10.2147/COPD.S
Khaled Albouaini, Mohammed Andron, Albert Alahmar, Mohaned Egred
Cardiothoracic Centre, Liverpool, England, UK
Abstract: The mortality and incidence of chronic obstructive pulmonary disease (COPD) and coronary heart disease increase with age. Despite the clear evidence of beta blockers (BBs) effectiveness, there is a general reluctance to use them in patients with COPD due to a perceived contraindication and fear of inducing adverse reactions and bronchspasm. BBs are well tolerated in patients with cardiac disease and concomitant COPD with no evidence of worsening of respiratory symptoms or FEV1, and the safety of BBs in patients with COPD has been demonstrated, but their use in this group of patients remains low. The cumulative evidence from trials and meta-analysis indicates that cardioselective BBs should not be withheld in patients with reactive airway disease or COPD.
Patients with COPD have a high incidence of cardiac events necessitating careful consideration of prophylactic treatment. The benefits of beta blockade in this group appear to outweigh any potential risk of side effects according to the available evidence.
In this article, we will discuss the use of BBs in patients with COPD and review the evidence for their use and safety in this group of patients.
Readers of this article also read:
Influenza: the virus and prophylaxis with inactivated influenza vaccine in “at risk” groups, including COPD patients
Long-term oxygen therapy: Are we prescribing appropriately?
The influence of the media on COPD patients’ knowledge regarding cardiopulmonary resuscitation
Knowledge and attitudes of family physicians coming to COPD continuing medical education
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives
Retinal nerve fiber layer thickness in recovered and persistent amblyopia
Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK
Primary care for diabetes mellitus: perspective from older patients
- Journal Indexing
See where all the Dove Press journals are indexed
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- Clinical effectiveness of the Respimat® inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices
- Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity
- The pathophysiology of bronchiectasis
- Exacerbation rate, health status and mortality in COPD – a review of potential interventions




